Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Aug;108(2):190.
doi: 10.1002/cpt.1878. Epub 2020 May 21.

Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2"

Yin-Xiao Du  1   2   3 , Xiao-Ping Chen  1   2   3
Affiliations
Comment

Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2"

Yin-Xiao Du et al. Clin Pharmacol Ther. 2020 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declared no competing interests for this work.

Comment on

References

    1. Eloy, P. et al. Dose rationale for favipiravir use in patients infected with SARS‐CoV‐2. Clin. Pharmacol. Ther. 108, 188 (2020). - PubMed
    1. Du, Y.X. & Chen, X.P. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019‐nCoV infection. Clin. Pharmacol. Ther. 108, 242–247 (2020). - PubMed
    1. Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019‐nCoV) in vitro. Cell Res. 3, 269–271 (2020). - PMC - PubMed
    1. Choy, K.‐T. et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS‐CoV‐2 replication in vitro. Antiviral. Res. 3, 178 (2020). - PMC - PubMed
    1. Chen, C. et al. Favipiravir versus arbidol for COVID‐19: a randomized clinical trial. bioRxiv. 10.1101/2020.03.17.20037432. [e‐pub ahead of print]. - DOI